Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Double-crosslinked carrageenan/gelatin hydrogel loaded with heparin for heart valve tissue engineering applications.

Guo C., Ye W., Huang J., Xiao J., Lu D., Gao B.

Animal Study on Systemic / IV, published in Biomed Mater (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Biomed Mater (2026)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41871531
DOI
10.1088/1748-605X/ae55ee

Abstract (original English)

The development of tissue-engineered heart valves (TEHVs) remains a challenge worldwide. In this study, a series of double-crosslinked methacrylated (MA) carrageenan (CA)/MA gelatin hydrogels loaded with heparin (CA/Gel@Hep) were developed as potential materials for TEHV. CA/Gel@Hep hydrogels with different concentrations of heparin were fabricated, and their mechanical properties, swelling/degradation behaviors, and heparin release profiles, and biological performance were systematically studied. The rheological tests showed that storage modulus ( G ') was consistently higher than loss modulus ( G ''). Unconfined compression tests showed that the compressive modulus of CA/Gel@Hep hydrogels ranged from 0.26 ± 0.01 to 0.43 ± 0.03 kPa, which matches the mechanical requirements of native valve leaflets. In vitro evaluation demonstrated that CA/Gel@Hep hydrogels exhibited good cytocompatibility and blood compatibility, excellent anticoagulant properties, and facilitated migration and proliferation of human adipose tissue-derived mesenchymal stromal cells. quantitative PCR results showed that CA/Gel@Hep hydrogels significantly upregulated the expression of genes related to valve remodeling, including SMA, VIM, MMP1, and MMP2. These results suggest that CA/Gel@Hep hydrogels hold great potential for heart valve tissue engineering applications.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Tissue EngineeringGelatinHydrogelsHumansHeparinMesenchymal Stem CellsCarrageenanHeart Valve ProsthesisCell ProliferationHeart Valves

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research